Button J, Kanu E, Agritelley E, Dickey EM, et al. SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer: A Multicenter, Retrospective Cohort Study. Ann Surg 2025 Oct 28. doi: 10.1097/SLA.0000000000006966.
PMID: 41147557